centchroman has been researched along with Breast Neoplasms in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Gopi, M; Gopimohan, R; Maya, V; Pillai, LS; Ramaswami, K; Ravindran, S; Regidi, S; Varghese, J; Varghese, SD | 1 |
| Culig, Z | 1 |
| Agrawal, S; Ahmad, H; Arya, A; Dwivedi, AK; Dwivedi, M; Lal, J; Sharma, K; Shukla, M | 1 |
| Agarwal, S; Balapure, AK; Dwivedi, AK; Kaushik, S; Nag, TC; Sharma, R; Shyam, H | 1 |
| Farhan, M; Kannan, A; Khan, S; Lakra, AD; Meeran, SM; Penta, D; Shukla, S; Sinha, S | 1 |
| Balapure, AK; Dewangan, J; Kaushik, S; Rath, SK | 1 |
| Balapure, AK; Kaushik, S; Sharma, R; Shyam, H | 1 |
| Hou, J; Li, P; Mi, M; Xiong, X; Xu, X; Zeng, J | 1 |
| Bora, HK; Khan, S; Lakra, AD; Meeran, SM; Shukla, S; Sinha, S | 1 |
| Balapure, AK; Gupta, DK; Nigam, D; Nigam, M; Ranjan, V; Sharma, R; Singh, N; Sundaram, S; Zaidi, D | 1 |
| Dhar, A; Srivastava, A | 1 |
| Balapure, AK; Nigam, M; Ranjan, V; Sharma, R; Srivastava, S | 1 |
| Giri, AK; Hsie, AW; Mukhopadhyay, A; Ray, S; Sun, J | 1 |
| Agarwal, AK; Gupta, R; Kamboj, VP; Misra, NC; Nigam, PK | 1 |
1 review(s) available for centchroman and Breast Neoplasms
| Article | Year |
|---|---|
Epithelial mesenchymal transition and resistance in endocrine-related cancers.
Topics: Benzopyrans; Breast Neoplasms; Cadherins; Cell Plasticity; Cytokines; Disease Progression; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; Female; Humans; Inflammation; Male; MAP Kinase Kinase 5; Metformin; MicroRNAs; Prostatic Neoplasms; Proto-Oncogene Proteins c-fos; Receptor, ErbB-2; Signal Transduction; Transforming Growth Factor beta | 2019 |
13 other study(ies) available for centchroman and Breast Neoplasms
| Article | Year |
|---|---|
Nonhormonal selective estrogen receptor modulator 1-(2-[4-{(3R,4S)-7-Methoxy-2, 2-dimethyl-3-phenyl-chroman-4yl}phenoxy]ethyl)pyrrolidine hydrochloride (ormeloxifene hydrochloride) for the treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Benzopyrans; Breast Neoplasms; Cells, Cultured; Drug Screening Assays, Antitumor; Female; Humans; Mice; Selective Estrogen Receptor Modulators | 2018 |
PEGylated chitosan nanoparticles potentiate repurposing of ormeloxifene in breast cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzopyrans; Breast; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Repositioning; Female; Humans; MCF-7 Cells; Nanoparticles; Polyethylene Glycols; Rats, Sprague-Dawley | 2016 |
Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Centchroman; Drug Synergism; Female; Genistein; Humans; Isoflavones; MCF-7 Cells; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Phosphatidylinositol 3-Kinases; Phytoestrogens; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction | 2019 |
Centchroman prevents metastatic colonization of breast cancer cells and disrupts angiogenesis via inhibition of RAC1/PAK1/β-catenin signaling axis.
Topics: Animals; beta Catenin; Breast Neoplasms; Centchroman; Estrogen Antagonists; Female; Human Umbilical Vein Endothelial Cells; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Neuropeptides; p21-Activated Kinases; rac1 GTP-Binding Protein; Random Allocation; Signal Transduction | 2020 |
Centchroman regulates breast cancer angiogenesis via inhibition of HIF-1α/VEGFR2 signalling axis.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Apoptosis; Breast; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Centchroman; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; MAP Kinase Signaling System; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Dietary isoflavone daidzein synergizes centchroman action via induction of apoptosis and inhibition of PI3K/Akt pathway in MCF-7/MDA MB-231 human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Centchroman; Drug Synergism; Female; Humans; Isoflavones; MCF-7 Cells; Membrane Potential, Mitochondrial; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2018 |
[Effect of xy2004, a centchroman derivative, on proliferation of MCF-7 cells in vitro and the mechanism].
Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Proliferation; Centchroman; Estrogen Receptor alpha; Estrogen Receptor beta; Humans; MCF-7 Cells; Proto-Oncogene Proteins c-bcl-2; Tamoxifen | 2014 |
Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Centchroman; Epithelial-Mesenchymal Transition; Humans; Immunohistochemistry; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Wound Healing | 2015 |
Centchroman mediated apoptosis involves cross-talk between extrinsic/intrinsic pathways and oxidative regulation.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Centchroman; Cycloheximide; Dactinomycin; Down-Regulation; Estrogen Antagonists; Female; Humans; Immunoprecipitation; Oxidative Stress; Tamoxifen; Up-Regulation | 2010 |
Role of centchroman in regression of mastalgia and fibroadenoma.
Topics: Adolescent; Adult; Breast Diseases; Breast Neoplasms; Centchroman; Estrogen Antagonists; Female; Fibroadenoma; Humans; Pain; Pain Measurement; Treatment Outcome; Ultrasonography, Mammary | 2007 |
Centchroman induces G0/G1 arrest and caspase-dependent apoptosis involving mitochondrial membrane depolarization in MCF-7 and MDA MB-231 human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Nucleus; Cell Shape; Cell Survival; Centchroman; Clinical Trials as Topic; DNA Fragmentation; Estrogen Antagonists; Female; G1 Phase; Humans; Membrane Potentials; Mitochondria; Resting Phase, Cell Cycle; Tamoxifen | 2008 |
Antimutagenic effects of centchroman--a contraceptive and a candidate drug for breast cancer in multiple mutational assays.
Topics: Animals; Antimutagenic Agents; Breast Neoplasms; Cells, Cultured; Centchroman; CHO Cells; Contraceptives, Postcoital, Synthetic; Cricetinae; Cyclophosphamide; Drug Screening Assays, Antitumor; Estrogen Antagonists; Female; Mice; Mice, Inbred Strains; Mitomycin; Mutagenicity Tests; Salmonella; Sister Chromatid Exchange | 1999 |
Centchroman--a non-steroidal anti-cancer agent for advanced breast cancer: phase-II study.
Topics: Adult; Aged; Antineoplastic Agents; Benzopyrans; Biomarkers, Tumor; Breast Neoplasms; Centchroman; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Receptors, Estrogen | 1989 |